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Context: There are several genetic and molecular evidences suggesting dysregulation of the mam-
malian target of rapamycin (mTOR) pathway in thyroid neoplasia. Activation of the phosphati-
dylinositol-3-kinase/AKT pathway by RET/PTC and mutant RAS has already been demonstrated, but
no data have been reported for the BRAFV600E mutation.
Objective: The aim of this study was to evaluate the activation pattern of the mTOR pathway in
malignant thyroid lesions and whether it may be correlated with known genetic alterations, as well
as to explore the mechanisms underlying mTOR pathway activation in these neoplasias.
Results: We observed, by immunohistochemical evaluation, an up-regulation/activation of the
mTOR pathway proteins in thyroid cancer, particularly in conventional papillary thyroid carcinoma
(cPTC). Overactivation of the mTOR signaling was particularly evident in cPTC samples harboring
the BRAFV600E mutation. Transfection assays with BRAF expression vectors as well as BRAF knock-
down by small interfering RNA revealed a positive association between BRAF expression and mTOR
pathway activation, which appears to be mediated by pLKB1 Ser428, and emerged as a possible
mechanism contributing to the association between BRAF mutation and mTOR pathway up-reg-
ulation. When we evaluated the rapamycin in the growth of thyroid cancer cell lines, we detected
that cell lines with activating mutations in the MAPK pathway show a higher sensitivity to this drug.
Conclusions: We determined that the AKT/mTOR pathway is particularly overactivated in human
cPTC harboring the BRAFV600E mutation. Moreover, our results suggest that the mTOR pathway
could be a good target to enhance therapy effects in certain types of thyroid carcinoma, namely
in those harboring the BRAFV600E mutation. (J Clin Endocrinol Metab 97: E1139–E1149, 2012)
Abnormalities in the mammalian target of rapamycin(mTOR) signaling pathway have emerged as com-
mon events observed in different types of cancer (1).
mTOR is a serine/threonine kinase that functions as a cen-
tral regulator of cell growth-related processes (2) and can
be found in two distinct complexes: mTORC1 and
mTORC2. mTOR and its associated proteins mLST8/
GL, PRAS40, and raptor constitute the mTORC1,
whose kinase activity is sensitive to rapamycin. S6 kinase
1 and eIF4E-binding protein (4EBP1) are the main
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mTORC1 effectors (3). mTORC2, composed of mTOR,
mLST8/GL, mSIN1, protor, and rictor, is insensitive to
acute rapamycin treatment and is involved in the regula-
tion of cell proliferation and survival through phosphor-
ylation of AKT (at Ser473) (4).
mTOR regulates cell growth by integrating signals de-
rived from different inputs (2). Regulation of mTOR by
growth factors classically occurs through the phosphati-
dylinositol-3-kinase (PI3K)/AKT pathway, which is coun-
teracted by the phosphatase and tensin homolog (PTEN).
The cellular energy status is connected to mTORC1
through AMP-activated protein kinase (AMPK), which is
activated in response to energy stress (5). The tumor sup-
pressor liver kinase B1 (LKB1) has been identified as the
main upstream kinase of AMPK (6). LKB1 binds and
phosphorylates AMPK on its Thr172, activating this ki-
nase in case of energy deprivation, which in turn inhibits
mTORC1 signaling (7). Recent data reported that BRAF
mutant melanoma cells have a dysfunctional LKB1-
AMPK-mTOR energy stress sensor (8, 9). In BRAFV600E-
transformed melanoma cells, LKB1 is phosphorylated by
the BRAFV600E downstream kinases ERK and p90RSK,
compromising its ability to bind and activate AMPK (8).
Mutations or rearrangement of genes codifying for
components of the MAPK pathway seem to be crucial for
the transformation process in thyroid (10), and thyroid
tumors show a strong genotype-phenotype relationship
(11). Papillary thyroid carcinoma (PTC) is the most com-
mon thyroid malignancy [85–90% (10)], being genetically
characterized by a high incidence of mutations in the
BRAF gene (particularly BRAFV600E) and by RET/PTC
rearrangements (12, 13).
In thyroid lesions, information on mTOR expression is
not available, to the best of our knowledge. Despite this,
PI3K/AKT pathway genetic alterations have been re-
ported in follicular thyroid carcinoma (FTC) and PTC,
namely PTEN promoter hypermethylation (14), PTEN
loss of heterozygosity (15, 16), and PI3KCA amplification
(17, 18), suggesting a role for mTOR signaling in thyroid
neoplasia. Furthermore, previous data demonstrated that
RET/PTC rearrangements and RAS mutations can lead to
the activation of the PI3K/AKT pathway (19–23),
whereas no data have been reported for the BRAFV600E
mutation.
The aims of this study were to evaluate the activation
pattern of the mTOR signaling pathway in malignant thy-
roid lesions, to verify whether it may be correlated with
known genetic alterations, and to explore the mechanisms
underlying mTOR pathway activation in these neoplasias.
Materials and Methods
Thyroid samples and tissue microarray
construction
Thyroid tissue specimens [formalin-fixed paraffin-embedded
(FFPE)] of 133 patients were collected from the files of the Hos-
pital São João/Medical Faculty of the University of Porto, Por-
tugal; the Institute of Molecular Pathology and Immunology of
the University of Porto (IPATIMUP), Portugal; Clinical Univer-
sity Hospital (CHUS), University of Santiago de Compostela,
Spain; and Hospital S Marcos, Portugal. Cases were histologi-
cally classified by experienced pathologists (J.M.C.-T., F.P., and
M.S.-S.) in FTC (n  20), follicular variant of PTC (FVPTC; n 
22), conventional PTC (cPTC; n  60), and cPTC metastases
(n  21), and representative areas were selected. Areas of adja-
cent normal thyroid (n  34) were also selected. Duplicate tissue
cores 2.0 mm in diameter were extracted from the selected areas
and arrayed on a recipient paraffin block. All procedures with
samples were in accordance with the institutional and national
ethical rules.
Immunohistochemistry
The following antibodies were used: rabbit monoclonal an-
tibodies specific for PTEN (1:75), phospho-AKT Ser473 (1:50),
phospho-AKT Thr308 (1:50), mTOR (1:50), phospho-S6
Ser235/236 (1:75), phospho-4EBP1 Thr37/46 (1:200), raptor
(1:75), and phospho- LKB1 Ser428 (1:50), all from Cell Signal-
ing Technology (Danvers, MA); rabbit polyclonal antibody spe-
cific for phospho-mTOR Ser2448 (1:50; Cell Signaling Tech-
nology); and antirictor mouse monoclonal antibody (1:500;
Abnova, Jhongli City, Taiwan). The antibodies were validated in
previous work of our group for immunohistochemical analysis in
FFPE samples (24, 25).
Sections were subjected to heat-induced antigen retrieval in 1
mM EDTA (pH 8.0) for the anti-phospho-S6 Ser235/236 anti-
body or in 10 mM sodium citrate buffer (pH 6.0) for the remain-
ing antibodies, followed by blocking of endogenous peroxidase
activity (3% of H2O2) and of nonspecific binding with Large
Volume Ultra V Block reagent (Thermo Scientific/Lab Vision,
Fremont, CA). Sections were incubated with the primary anti-
body overnight at 4 C. Negative controls were carried out by
omitting the primary antibody.
The detection was performed with a labeled streptavidin-bi-
otin immunoperoxidase detection system (Thermo Scientific/
Lab Vision) followed by 3,3-diaminobenzidine incubation. For
the anti-phospho-AKT Thr308 antibody, the immunostaining
was performed with an alkaline phosphatase kit (Dako,
Glostrup, Denmark), and the samples were developed with a
permanent red chromogen.
The immunostaining was blindly semiquantitatively evalu-
ated in terms of staining intensity (0, negative; 1, weak; 2, in-
termediate; 3, strong) and percentage of stained cells (0, 5%;
1, 5 to 25%; 2, 25 to 50%; 3, 50 to 75%; 4, 75%). An im-
munohistochemical score was calculated by multiplying the pro-
portion of positive cells by the intensity of the staining, with 12
being the maximum score. The cellular localization was also
evaluated as membranar and/or cytoplasmic and/or nuclear.
DNA extraction and mutational analysis of BRAF
Selected representative areas were manually dissected from
10-m sections of FFPE cases of cPTC. DNA extraction was
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based on salting-out technology (CitogeneDNA Purification
Kits; Citomed, Lisbon, Portugal).
Screening for BRAF mutations was restricted to exon 15,
which was amplified by PCR and sequenced on an ABI Prism
3130 xl Automatic sequencer (Perkin-Elmer, Foster City, CA).
Cell lines, BRAF vectors, and transfection assays
T243, TPC1, K1, 8505C, C643, T241, and XTC-1 thyroid
cancer cell lines used in this study were already characterized at
the molecular and genotypic level (Supplemental Table 5) (26,
27). All cell lines were maintained in RPMI supplemented with
10% (vol/vol) fetal bovine serum (FBS) and antibiotics [1% (vol/
vol) Pen Strep and 0.5% (vol/vol) fungizone; all from GIBCO,
Invitrogen, Carlsbad, CA], except XTC-1, which was cultured in
DMEM/F12 (GIBCO, Invitrogen) supplemented with 10% (vol/
vol) FBS, insulin at 10 g/ml, TSH at 10mU/ml (Sigma-Aldrich,
St. Louis, MO), and antibiotics. Human embryonic kidney
(HEK293) cells used in the transfection assays were cultured in
DMEM supplemented with 10% (vol/vol) FBS and antibiotics.
All cells were grown in a humidified incubator with 5% CO2 at
37 C.
The expression vectors for BRAF were constructed in-house
by insertion of the coding sequences of BRAFWT and BRAFV600E
into the multiple cloning site of pCMV empty vector (pCMV-
BRAFWT and pCMV-BRAFV600E). After transformation, the
clones were subjected to automated sequencing to verify the in-
tegrity of the BRAF sequence.
For transfection assays, HEK293 cells were transiently trans-
fected by the calcium phosphate coprecipitation method with 5
g of DNA, including 100 ng of expression plasmid (pCMV-
empty vector, pCMV-BRAFwt, or pCMV-BRAFV600E), 100 ng
of pEGFP-C1 (Clontech, Mountain View, CA) to monitor trans-
fection efficiency, and 4.8 g of “carrier DNA”- pUC18. Con-
firmation of BRAF expression as well as of pERK 1/2 (as a read-
out of BRAF activity) was done by Western blotting.
The small interfering RNA (siRNA) assays were performed as
previously reported (28), using 50 nM of oligo BRAF (BRAF-C2)
and 25 nM of LKB1 siRNA (Smartpool from Dharmacon;
Thermo Scientific). Cells were seeded and transfected with Li-
pofectamine 2000, and cell lysates were obtained after 48 h.
BRAF and LKB1 down-regulation was confirmed by Western
blotting.
Growth inhibition assay
The growth of thyroid cancer cell lines (3  103 C643 and K1
cells; 5  103 8505C and TPC1 cells; 6  103 XTC-1 and T243
cells; and 8  103 T241 cells) was assessed after 48 h of rapa-
mycin treatment (range, 0.1 to 1000 nM) by the sulforhodamine
B (SRB) assay. Cells were fixed with 50% (wt/vol) trichloroacetic
acid and stained with a 0.1% (wt/vol) SRB solution. SRB was
solubilized in a 10 mM Tris-base buffer, and the absorbance was
read at 560 nm.
Western blotting
Cells were lysed in RIPA buffer supplemented with phospha-
tase and protease inhibitors. Proteins were resolved by SDS-
PAGE and transferred onto nitrocellulose membranes (GE
Healthcare, Little Chalfont, UK). The primary antibodies were
referred in the immunohistochemistry section and used at a
1:1000 dilution. Anti-phospho-44/42 MAPK (pERK 1/2)
(Thr202/Tyr204) (1:1000; Cell Signaling Technology) and anti-
BRAF (1:500; Santa Cruz Biotechnology, Santa Cruz, CA) pri-
mary antibodies were also used.
Protein was detected using a horseradish peroxidase-conju-
gated secondary antibody (Santa Cruz Biotechnology) and a lu-
minescence system (Perkin-Elmer). For protein-loading control,
membranes were reprobed with an anti--Tubulin (Sigma-Al-
drich) or an anti-actin (Santa Cruz Biotechnology) antibody.
Protein expression was quantified using the Bio-Rad Quantity
One 1-D Analysis software (Bio-Rad Laboratories, Inc., Hercu-
les, CA) and normalized by the levels of actin or -Tubulin.
Statistical analysis
Statistical analysis was done using StatView version 5.0 soft-
ware (SAS Institute Inc., Cary, NC). All data are expressed as
mean  SEM. Differences between groups were examined by the
unpaired Student’s t test and the Mann-Whitney U test. P values
0.05 were considered statistically significant.
Results
Overexpression of mTOR pathway proteins in
malignant thyroid lesions
The proportion of immunopositive cases observed in the
different histological types and the respective immunohisto-
chemical scores are summarized in Fig. 1 and in Supplemen-
tal Tables 1 and 2 (published on The Endocrine Society’s
Journals Online web site at http://jcem.endojournals.org).
Information relative to the cellular localization of the stain-
ing is provided in Supplemental Table 3.
PTEN expression was observed in all malignant lesions
with significantly higher staining scores than in normal
thyroid (P  0.0001 to 0.0026; Fig. 1). Additionally, an
increase in cytoplasmic PTEN and a decrease in the pro-
portion of cells with nuclear PTEN were observed, par-
ticularly in cPTC (Supplemental Table 3).
A statistically significant increased expression of pAKT
Ser473, relative to normal tissue, was observed in cPTC
and cPTC metastases (P  0.0001 and P  0.0082, re-
spectively; Fig. 1). The pAKT Thr308 protein was ob-
served in almost all the cases of thyroid carcinoma with a
significantly elevated expression when compared with
normal thyroid tissue (P  0.0001; Fig. 1).
Enhanced expression of mTOR and phosphorylated
mTOR (pmTOR) Ser2448 was detected in FTC, FVPTC,
and cPTC, when compared with normal thyroid tissue
(P  0.0001 to 0.0022; Fig. 1). Total mTOR expression
was significantly higher in cPTC, relative to the other car-
cinoma histotypes (P  0.0001 to 0.0022). The levels of
pmTOR in cPTC were significantly higher than in FVPTC
and cPTC metastases (P  0.0108 and P  0.0005, re-
spectively) and were borderline higher than in FTC (P 
0.0589).
Raptor and rictor were overexpressed (P  0.0001 to
0.0007; Fig. 1) in thyroid lesions in comparison to normal
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tissue. In cPTC, rictor score was significantly higher than
in FTC and FVPTC (P  0.0094 and P  0.0023,
respectively).
A significant increase in the expression of mTORC1
downstream targets, pS6 Ser235/236 and p4EBP1 Thr37/
46, relative to normal thyroid tissue, was observed only in
cPTC samples (P  0.0180 and P  0.0001, respectively;
Fig. 1).
In primary cPTC, we found significantly higher expres-
sion of PTEN (P  0.0086), pAKT Ser473 (P  0.0477),
mTOR (P  0.0001), pmTOR (P  0.0005), and p4EBP1
Thr37/46 (P  0.0011) than in cPTC metastases.
These results show that, in thyroid cancer, particularly
in cPTC, mTOR pathway proteins are overexpressed.
Overexpression of mTOR pathway proteins in cPTC
with BRAFV600E mutation
Because we observed distinct expression of mTOR
pathway proteins across the different histotypes, with par-
ticular overactivation in cPTC, and knowing the close ge-
notype- phenotype correlation in thyroid tumors, we ver-
ified whether the expression of mTOR pathway proteins
in cPTC was correlated with the presence of the BRAF
mutation. BRAFV600E mutation was present in 23 of the
60 (38.3%) cPTC cases.
We observed a significantly higher expression of pAKT
Ser473 (P  0.0001), mTOR (P  0.0001), pmTOR
Ser2448 (P  0.0001), raptor (P  0.0037), rictor (P 
0.0323), and pS6 Ser235/236 (P  0.0084) in cPTC-
BRAFV600E than in cPTC-BRAFwt (Fig. 2, A and B, and
Supplemental Table 4).
These observations suggest that BRAFV600E-mutated
cPTC is associated to a higher activation of the mTOR
pathway.
Regulation of mTOR pathway activation by BRAF
To verify the possible effects of BRAFV600E in the ac-
tivation of the mTOR pathway, we transiently transfected
HEK293 cells with control pCMV, pCMV-BRAFwt, or
pCMV-BRAFV600E vectors. Additionally, we down-reg-
ulated BRAF by siRNA in thyroid cancer cell lines and
analyzed the alterations on the levels of mTOR pathway
effectors.
As observed in Fig. 3A, after transfection with pCMV-
BRAFwt and pCMV-BRAFV600E, an increase in the mean
fold expression of mTOR (2.8  0.9 and 3.3  1.1, re-
spectively), pmTOR Ser2448 (2.5  0.6 and 2.2  0.2,
respectively), raptor (1.8  0.4 and 2.1  0.7, respec-
tively), rictor (1.9  0.6 and 2.4  1.1, respectively), and
pS6 Ser235/236 (1.9  0.5 and 2.0  0.3, respectively)
was observed relative to pCMV-empty vector. The
pCMV-BRAFV600E expression led to significant enhanced
pmTOR Ser2448 and pS6 Ser235/236 levels (P  0.0023
and P  0.0284, respectively; Fig. 3, A and B).
The levels of mTOR pathway effectors were evaluated
in K1, 8505C, TPC1, C643, and T241 thyroid cancer cell
lines after BRAF down-regulation by siRNA. As observed
in Fig. 4A, BRAF-C2 siRNA led to down-regulation of
BRAF expression in all cell lines, although less efficiently
in TPC1. Decrease of pERK1/2 was observed in all the cell
lines, except in C643. In K1, such a difference was statis-
tically significant (P  0.0002). In K1, 8505C, and C643,
FIG. 1. Expression of mTOR pathway proteins in normal thyroid and malignant thyroid lesions. The immunostaining of PTEN, pAKT Thr308, pAKT
Ser473, mTOR, pmTOR Ser2448, raptor, rictor, pS6 Ser235/236, and p4EBP1 Thr37/46 was evaluated in normal thyroid (NT), FTC, FVPTC, cPTC,
and cPTC metastases. The antigen expression was represented by a score calculated through multiplication of the value attributed to the staining
intensity (0 to 3) by the value attributed to the percentage of stained cells (0 to 4) (maximum value is therefore 3  4  12). Results are shown as
mean score  SEM. *, P  0.05; **, P  0.01; ***, P  0.001 (unpaired Student’s t test and Mann-Whitney U test).
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a significant decrease of pmTOR Ser2448 was observed
upon BRAF silencing (P  0.0039 to 0.0127; Fig. 4B),
whereas this treatment led to significant reduced expres-
sion of pS6 Ser235/236 in the five cell lines (P  0.0004 to
0.0252; Fig. 4B).
These in vitro results reveal a positive association be-
tween BRAF expression and mTOR pathway activation
and support the correlation between BRAFV600E and
overactivation of the mTOR pathway observed in cPTC
cases, particularly the overexpression of pmTOR Ser2448
and pS6 Ser235/236.
Oncogenic alterations in the ERK/MAPK pathway
predict higher sensitivity of thyroid cancer cell
lines to rapamycin
Basal activation of mTOR pathway was observed in the
seven studied cell lines (Supplemental Fig. 1).
The sensitivity of thyroid cancer cell lines to rapa-
mycin was compared. As observed in Fig. 5, A and B,
rapamycin inhibited the growth of the seven cell lines,
which was particularly evident at 10 and 100 nM con-
centrations (Supplemental Table 5). 8505C, K1, T243,
FIG. 2. Expression of mTOR pathway proteins in cPTC with and
without BRAFV600E mutation. A, The immunostaining of PTEN, pAKT
Thr308, pAKT Ser473, mTOR, pmTOR Ser2448, raptor, rictor, pS6
Ser235/236 and p4EBP1 Thr37/46 was evaluated. The expression score
was obtained by multiplying the value attributed to the staining
intensity by the value attributed to the percentage of stained cells.
Results are shown as mean  SEM. *, P  0.05; **, P  0.01; ***, P 
0.001 (unpaired Student’s t test and Mann-Whitney U test). B,
Microphotographs representative of the immunohistochemical staining
of pAKT Ser473, mTOR, pmTOR Ser2448, and pS6 Ser235/236 in
cPTC-BRAFwt and cPTC-BRAFV600E cases. For all the evaluated proteins,
the immunohistochemical staining was performed with 3,3-
diaminobenzidine. Microphotographs were obtained at a 400
magnification.
FIG. 3. mTOR pathway activation in transfected cells expressing
exogenous BRAFwt or BRAFV600E. A, Mean fold change of protein
expression observed in HEK293 cells transfected with the expressing
vectors pCMV-BRAFwt and pCMV-BRAFV600E in comparison to cells
transfected with a pCMV-empty vector. The levels of PTEN, pAKT
Thr308, pAKT Ser473, mTOR, pmTOR Ser2448, raptor, rictor, pS6
Ser235/236, and p4EBP1 Thr37/46 were quantified and normalized by
the levels of control protein (actin or -Tubulin). Results are shown as
mean expression value  SEM of at least three independent
experiments. *, P  0.05; **, P  0.01 (unpaired Student’s t test). B,
Representative Western blot analysis of pmTOR Ser2448, mTOR, pS6
Ser235/236, and S6 expression levels in protein extracts of HEK293
cells transiently transfected with pCMV-empty vector and with the
expressing plasmids pCMV-BRAFwt or pCMV-BRAFV600E. The levels of
BRAF were analyzed for control of transfection efficiency, and the
levels of pERK 1/2 were used as readout of BRAF activity.
Representative actin expression pattern is shown.
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TPC1, and C643 showed significantly higher growth
inhibition than XTC1 and T241. Altogether, at 1 to
1000 nM doses, a lower sensitivity to rapamycin was
observed in cell lines without MAPK alterations, com-
pared with the ones harboring MAPK oncogenic alter-
ations (P  0.0001; Fig. 5B).
In all seven cell lines, rapamycin remarkably reduced
the levels of pS6 Ser235/236 (Fig. 5C), at 10 and 100 nM.
Upon drug treatment, a decrease of pmTOR Ser2448 was
also observed, except for the XTC-1 cell line.
These results indicate that oncogenic mutations in the
MAPK pathway may confer higher sensitivity of thyroid
cancer cell lines to rapamycin treatment.
BRAFV600E expression regulates the levels of pLKB1
Ser428
To assess a possible mechanism underlying the link be-
tween BRAFV600E mutation and mTOR pathway activa-
tion observed in cPTC, we evaluated the levels of pLKB1
Ser428 in HEK293 cells transfected with pCMV-empty
vector, pCMV-BRAFwt, or pCMV-BRAFV600E as well as
in thyroid cancer cell lines with BRAF knockdown by
siRNA.
Increased expression of pLKB1 Ser428 was observed
upon transfection with both BRAF expression vectors
compared to cells transfected with the empty vector: 2.2 
0.8-fold for pCMV-BRAFwt, and 6.0  1.5-fold for
pCMV-BRAFV600E (Fig. 6A); the 6-fold increase of
pLKB1 Ser428 expression observed in pCMV-BRAFV600E
transfected cells was statistically significant (P  0.0313;
Fig. 6A).
At basal levels, pLKB1 Ser428 was barely detectable in
C643 and T241. A decrease in pLKB1 Ser428 expression
was observed in K1 (6.0  0.06-fold), 8505C (2.3  0.03-
fold), and TPC1 (2.5  0.2-fold) upon BRAF-C2 siRNA
(Fig. 6B), which was only significant in the BRAFV600E cell
lines, K1 and 8505C (P  0.0019 and P  0.0009, re-
spectively). We down-regulated LKB1 in 8505C, TPC1,
and K1 by siRNA. pLKB1 Ser 428 expression was con-
firmed to be decreased in 8505C and TPC1 (Fig. 6C),
whereas it failed to be efficiently down-regulated in K1
(data not shown). In parallel, a significant up-regulation of
pS6 Ser235/236 was detected in 8505C and TPC1 cell
lines (P  0.03 and 0.02, respectively; Fig. 6C).
We analyzed the expression of phospho- LKB1 in our
series of primary PTC characterized for BRAFV600E muta-
tion. We observed that BRAFV600E positive cases had higher
phospho- LKB1 levels compared with BRAFwt cases (mean
scores, 7.1 vs. 6.4, respectively), although the difference did
not reach statistical significance (t test, P  0.33).
FIG. 4. mTOR pathway expression in thyroid cancer cells lines with BRAF silencing. A, Western blot analysis of pmTOR Ser2448, mTOR, pS6
Ser235/236, and S6 expression levels in protein extracts of K1, 8505C, TPC1, C643, and T241 thyroid cancer cell lines treated with BRAF-C2
siRNA. The levels of BRAF were analyzed for control of silencing efficiency, and the levels of pERK 1/2 as readout of BRAF activity. Representative
actin expression pattern is shown. Protein level, in scramble siRNA-treated cell lines, was evaluated in duplicate (Scr), whereas in BRAF siRNA-
treated cell lines, it was analyzed in triplicate. B, Mean fold change of protein expression observed in K1, 8505C, TPC1, C643, and T241 thyroid
cancer cell lines treated with BRAF-C2 siRNA in comparison to cells treated with scramble siRNA. The levels of pmTOR Ser2448 and pS6 Ser235/
236 were quantified and normalized by the levels of control protein (actin or -Tubulin). Results are shown as mean expression value  SEM. *,
P  0.05; **, P  0.01; ***, P  0.001 (unpaired Student’s t test).
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Taken together, these results suggest that increased
phosphorylation of pLKB1 Ser428 can be a mechanism
contributing to the mTOR pathway overactivation ob-
served in BRAFV600E thyroid cancer cells.
Discussion
In the present study, we observed a particularly evident
overactivation of AKT/mTOR pathway in cPTC. A sig-
nificantly higher expression of mTOR pathway proteins
was detected in cPTC compared with normal tissue and
with the other types of differentiated thyroid carcinoma.
Our immunohistochemical results fit with the previously
reported increased expression of phospho-p70S6K and
pAKT Ser473 in PTC tissues (29, 30). We observed a sig-
nificantly higher up-regulation of the mTOR pathway in
BRAFV600E mutated cPTC compared with BRAFwt cPTC.
As far as we are aware, this is the first time that a corre-
lation between BRAFV600E mutation and overactivation
of the mTOR pathway is demonstrated in cPTC. In a pre-
vious work of our group, BRAFV600E-mutated cutaneous
melanomas also showed up-regulation of mTOR pathway
(25), suggesting that this effect is not tumor-type specific.
Paradoxically, PTEN levels were also higher in cPTC,
although with a preferential cytoplasmic localization. In
fact, a decrease in PTEN nuclear localization was detected
in these cases, which is in agreement with previous data
showing reduced intensity of nuclear PTEN staining in
PTC (16). Recent evidence showed that PTEN posttrans-
lational regulation (e.g. ubiquitination, oxidation, or
phosphorylation) can have a role in cancer susceptibility
by leading to inactive cytoplasmic forms and/or to defi-
cient PTEN nuclear import (31–33).
In cPTC metastases, the levels of PTEN, pAKT Ser473,
mTOR, pmTOR, and p4EBP1 were significantly lower
relative to primary lesions. These results suggest that the
FIG. 5. Rapamycin effect on thyroid cancer cell lines. A, TPC1, XTC1, 8505C, T243, K1, C643, and T241 were grown in 0 to 1000 nM of
rapamycin during 48 h, and the induced growth inhibition was determined by the SRB assay. Results were normalized to growth of cells treated
with dimethylsulfoxide (DMSO) and are represented as mean  SEM of six replicates. Differences between cell lines were evaluated by unpaired
Student’s t test. B, Growth inhibition observed in thyroid cancer cell lines, with (mutated) and without (wild-type) mutation in the MAPK pathway,
upon treatment with 0 to 1000 nM of rapamycin during 48 h. Results were normalized to growth of cells treated with DMSO and are represented
as mean  SEM of six replicates. Differences between the two groups were evaluated by unpaired Student’s t test. C, Western blot analysis of
rapamycin effect on the expression of AKT/mTOR pathway proteins. The levels of pS6 Ser235/236, S6, pmTOR Ser2448, and mTOR were detected
in thyroid cancer cell lines after treatment with 10 or 100 nM of rapamycin during 48 h. For each antibody, the image represented is the result of
grouping parts of the same gel, with the same exposure.
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mTORC1 pathway might be less active in cPTC metasta-
ses than in the primary lesions. Further work and a larger
cohort are needed to determine whether the discrepancy
observed between primary lesions and cPTC metastases
reflects true biological heterogeneity or biologically mean-
ingless quantitative differences.
The connection observed in cPTC between BRAFV600E
expression and mTOR pathway overactivation was fur-
ther supported by our in vitro results: BRAF overexpres-
sion led to enhanced pmTOR and pS6 expression, whereas
BRAF down-regulation led to reduced expression of these
proteins of the mTOR pathway. The up-regulation of
FIG. 6. Regulation of pLKB1 Ser428 levels by BRAFV600E expression. A, Western blot analysis of pLKB1 Ser428 expression levels in protein extracts of
HEK293 cells transiently transfected with pCMV-empty vector and with the expressing plasmids pCMV-BRAFwt or pCMV-BRAFV600E. Representative -
tubulin expression pattern is shown. The mean fold change of pLKB1 Ser428 levels in HEK293 cells transfected with the expressing vectors pCMV-BRAFwt
and pCMV-BRAFV600E in comparison to cells transfected with a pCMV-empty vector is shown in the graph. Results are shown as mean expression
value  SEM. *, P  0.05 (unpaired Student’s t test). B, Western blot analysis of pLKB1 Ser428 expression after treatment of K1, 8505C, TPC1, C643, and
T241 thyroid cancer cell lines with BRAF-C2 siRNA. In scramble siRNA-treated cell lines (Scr), protein levels were evaluated in duplicate, whereas in BRAF
siRNA-treated cell lines (BRAF-C2), it was analyzed in triplicate. The mean fold change of pLKB1 Ser428 levels in K1, 8505C, and TPC1 thyroid cancer cell
lines treated with BRAF-C2 siRNA in comparison to cells transfected with scramble siRNA is shown in the graph. Results are shown as mean expression
value  SEM. C, Western blot analysis of pLKB1 Ser428, pS6 Ser235/235 and total S6 protein levels after LKB1 knockdown by siRNA (LKB1 siRNA is
shown in duplicate). Actin was used as the loading control. Quantification of pS6 levels is shown on the right. Results represent mean  SEM of three
independent experiments. *, P  0.05; **, P  0.01; ***, P  0.001 (unpaired Student’s t test).
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mTOR signaling in BRAF-transformed HEK293 cells
was not exclusively associated with the mutated form of
BRAF, suggesting that overexpression of the wild-type
BRAF protein likely mimics the situation created by the
constitutional activation of BRAFV600E. Changes in
mTOR pathway upon BRAF siRNA were also observed
in cells harboring RAS mutation and RET/PTC. This
finding, together with the reported activation of the
PI3K/AKT/mTOR pathway in cells harboring those ge-
netic alterations or RET point mutation (19 –23, 34),
led us to speculate that BRAF may (at least partially)
modulate mTOR pathway activation in thyroid cells with
genetic alterations in the MAPK pathway. In line with
these observations, when we compared the sensitivity of
thyroid cancer cell lines to rapamycin, a significantly
higher growth inhibition was observed in thyroid cancer
cell lines with oncogenic alterations in the MAPK pathway
(BRAFV600E, RAS, and RET/PTC1).
Our results show for the first time that increased BRAF
signaling leads to mTOR pathway activation and suggest
that inhibition of both MAPK and mTOR pathways could
be a good strategy in therapeutic targeting of BRAFV600E-
positive tumors. In fact, previous data have shown an in-
creased or synergistic activity of BRAF (RAF265) or MEK
inhibitors (RDEA119, AZD6244) and mTOR inhibitors
(BEZ-235, temsirolimus, or rapamycin) in the growth in-
hibition of thyroid cancer cell lines and xenograft tumors
(35–37).
Additionally, we suggest a possible mechanism con-
tributing to the effect of oncogenic BRAF on mTOR path-
way activation. Specifically, we observed a positive cor-
relation between BRAFV600E expression and pLKB1 levels
in vitro. Moreover, LKB1 down-regulation by siRNA led
to activation of the mTOR pathway, as seen by increased
levels of pS6 in BRAFV600E as well as in RET/PTC-har-
boring thyroid cancer cell lines. As previously reported,
LKB1 activity can be negatively regulated by Ser428 phos-
phorylation induced by the RAF-MEK-ERK signaling cas-
cade as well as by p90-RSK (9). Therefore, it is plausible
that BRAFV600E mutations and RET/PTC rearrange-
ments, both activators of the ERK/MAPK pathway, can
induce LKB1 Ser428 phosphorylation, compromising its
ability to bind AMPK. In our series of human PTC, we
observed a tendency for BRAFV600E-harboring cases to
display increased pLKB1Ser428 levels, although it is un-
likely thatmutantBRAF is theonly factor regulatingLKB1
phosphorylation in these lesions in vivo.
Nonetheless, our results suggest that oncogenic BRAF-
induced inactivation of LKB1 by Ser428 phosphorylation
might underlie the mTOR pathway overactivation ob-
served in cell lines and in human tumors harboring the
BRAFV600E mutation.
These data further suggest that AMPK could be a good
target in BRAF-mutated thyroid cancer, which is in ac-
cordance with a recent report showing that AICAR
(AMPK activator) treatment inhibited the proliferation of
BRAFV600E mutant thyroid cancer cell lines more strongly
than of wild-type cell lines (38).
In PTC, BRAFV600E has been associated to a higher risk
of recurrence and radioactive iodine treatment resistance,
particularly due to decreased expression of Na/I sym-
porter (NIS)andits impairedtargetingtothemembrane(39).
A recent study demonstrated that rapamycin leads to an in-
crease in NIS expression and iodine uptake in insulin- and
TSH-stimulated thyroid PCCL3 cells (40). These previous
data and our finding of BRAFV600E association with over-
activation of mTOR pathway suggest that, in BRAFV600E
cPTC cases, the up-regulation of the mTOR pathway may
lead to a decrease in NIS expression, and therefore, the use of
mTOR inhibitors could be a strategy to increase the radio-
iodine response of BRAFV600E-cPTC.
In conclusion, we demonstrated that the AKT/mTOR
pathway is particularly overactivated in human cPTC har-
boring the BRAFV600E mutation. The association between
BRAFV600E mutation and mTOR pathway activation was
supported by in vitro results. BRAF-induced phosphory-
lation of LKB1Ser428 emerged as a possible mechanism
contributing to such association, possibly through uncou-
pling of the LKB1-AMPK-mTOR energy stress sensor.
Our results suggest and reinforce previous observations
showing that targeting the mTOR pathway (as well as in
combination with MAPK pathway/AMPK inhibition)
could be a good strategy to improve therapy effect in thy-
roid carcinomas harboring the BRAFV600E mutation.
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